Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bizaxofusp - Medicenna Therapeutics

Next Previous
Drug Profile

Bizaxofusp - Medicenna Therapeutics

Alternative Names: cpIL4-PE; Empowered Superkine targeting the IL-4R - Medicenna Therapeutics; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 22 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Neurocrine Biosciences; Sophiris Bio
  • Class Antineoplastics; Bacterial toxins; Immunotoxins; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma
  • Discontinued Bladder cancer; Diffuse intrinsic pontine glioma; Solid tumours

Most Recent Events

  • 22 Jul 2026 Discontinued - Preclinical for Diffuse intrinsic pontine glioma (In children) in USA (IV) (Medicenna Therapeutics Pipeline, July 2026)
  • 22 Jul 2026 Discontinued- research development in Bladder-cancer in USA (IV) (Medicenna Therapeutics Pipeline, July 2026)
  • 11 Jun 2026 Medicenna has patent protection for bizaxofusp worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top